Currently, it is still hard to give a conclusion that IL-7 can serve as an ideal adjuvant for cancer vaccines from such a limited number of clinical trials, therefore, clinical trials concerning IL-7 as an adjuvant for cancer vaccines, to fulfill efficacious T cell responses and long-lasting T cell memory against tumors, are urgently encouraged. This evidence concerns the gene IL7 and cancer.